Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy
Therapeutic Advances in Gastroenterology
Published online on January 19, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Vedolizumab (VED) is a gut-selective monoclonal antibody and an effective biological agent for many patients with inflammatory bowel disease (IBD). Therapeutic drug monitoring has been used to optimise treatment with other biological agents; however, the ...
Vedolizumab (VED) is a gut-selective monoclonal antibody and an effective biological agent for many patients with inflammatory bowel disease (IBD). Therapeutic drug monitoring has been used to optimise treatment with other biological agents; however, the ...